Articles From: M.D.C. Holdings Provides Preliminary Update On Net New Home Orders In Advance Of Milken Institute Global Conference to MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014


DENVER , April 29, 2014 /PRNewswire/ -- M.D.C. Holdings, Inc. (NYSE: MDC) today announced preliminary net new home order results for the quarter ended March 31, 2014 .
Sign-up for M.D.C. Holdings Provides Preliminary Update On Net New Home Orders In Advance Of Milken Institute Global Conference investment picks
DENVER , May 8, 2014 /PRNewswire/ -- M.D.C. Holdings, Inc. (NYSE: MDC) announced today that it will webcast a presentation being made at the J.P. Morgan 7th Annual Homebuilding and Building Products Conference on Thursday, May 15th at 1:15 p.m. ET .
Sign-up for M.D.C. Holdings' Presentation At The J.P. Morgan 7th Annual Homebuilding and Building Products Conference To Be Webcast Live investment picks
COLUMBUS, Ohio , May 6, 2014 /PRNewswire/ -- M/I Homes, Inc. (NYSE:MHO) announced today that its Board of Directors has declared a cash dividend of $0.609375 per share on its outstanding depositary shares (NYSE:MHO-PrA), each representing 1/1,000 th of a Series A Preferred Share of M/I Homes (the "Depositary Shares"), for the second quarter of 2014.
Sign-up for M/I Homes Announces Quarterly Cash Dividend on Preferred Shares investment picks
COLUMBUS, Ohio , May 7, 2014 /PRNewswire/ -- M/I Homes, Inc. (NYSE: MHO) announced today that senior management of the Company will make a presentation at the J.P. Morgan Homebuilders & Building Products Conference on Thursday, May 15, 2014 at 10:15 a.m. Eastern Time .
Sign-up for M/I Homes Presentation at the J.P. Morgan Homebuilders & Building Products Conference to be Webcast Live investment picks
COLUMBUS, Ohio , April 10, 2014 /PRNewswire/ -- M/I Homes, Inc. (NYSE: MHO) announces the following Webcast: What: M/I Homes, Inc. Announces First Quarter Earnings Webcast When: April 24, 2014 @ 4:00 p.m. Eastern Time Where: http://www.mihomes.com How: Live over the Internet -- Simply log on to the web at the address above.
Sign-up for M/I Homes, Inc. Announces First Quarter Earnings Webcast investment picks
COLUMBUS, Ohio , April 10, 2014 /PRNewswire/ -- M/I Homes, Inc. (NYSE: MHO) announces the following Webcast: What: M/I Homes, Inc. Announces First Quarter Earnings Webcast When: April 24, 2014 @ 4:00 p.m. Eastern Time Where: http://www.mihomes.com How: Live over the Internet -- Simply log on to the web at the address above.
Sign-up for M/I Homes, Inc. Announces First Quarter Earnings Webcast investment picks
BUFFALO, N.Y. , April 14, 2014 /PRNewswire/ -- M&T Bank Corporation ("M&T") (NYSE: MTB) today reported its results of operations for the quarter ended March 31, 2014 .
Sign-up for M&T Bank Corporation Announces First Quarter Results investment picks
2014/4/22
http://media.marketwire.com/attachments/201202/16057_M3logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1108463&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for M3AAWG Tackles Emerging Security Issues With Industry Collaboration; Also Announces 2014 Leadership investment picks
MEMPHIS, Tenn.
Sign-up for MAA Announces Quarterly Common Dividend investment picks
MEMPHIS, Tenn.
Sign-up for MAA Reports First Quarter Results investment picks
SAN DIEGO , May 12, 2014 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK) , aclinical stage oncology drug development company have entered into a definitive merger agreement.
Sign-up for MabVax Therapeutics And Telik Sign Definitive Merger Agreement investment picks
HOLLAND, Mich., April 28, 2014 (GLOBE NEWSWIRE) -- Macatawa Bank Corporation (Nasdaq:MCBC) (the "Company" or "Macatawa") today announced that its Board of Directors has declared a quarterly cash dividend of $0.02 per share of its common stock to be paid on May 29, 2014 to shareholders of record on May 8, 2014.
Sign-up for Macatawa Bank Corporation Declares Dividend investment picks
2014/4/29
SANTA MONICA, Calif.
Sign-up for Macerich Announces Quarterly Results investment picks
SANTA MONICA, Calif.
Sign-up for Macerich Declares The Quarterly Dividend On Its Common Shares investment picks
2014/4/25
http://media.marketwire.com/attachments/201204/41939_186C_smal_gradient_RGB.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1109698&ProfileId=051205&sourceType=1 MORAGA, CA --
Sign-up for MacKenzie Capital Management and MacKenzie Realty Capital, Inc. Announce a Tender Offer for Series 250, Series 60, and Series ES OP Units of Empire State Realty OP, LP. (NYSE Arca:FISK, NYSE Arca:OGCP, NYSE Arca:ESBA) investment picks
http://media.marketwire.com/attachments/200710/376942_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1110687&ProfileId=051205&sourceType=1 MANISTIQUE, MI --
Sign-up for Mackinac Financial Corporation Reports First Quarter 2014 Results investment picks
LOWELL, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- M/A-COM Technology Solutions Holdings, Inc. (Nasdaq:MTSI) (MACOM), a leading supplier of high performance RF, microwave, and millimeter wave products, today announced that its Mindspeed Technologies, Inc. subsidiary has entered into a definitive agreement to sell its CPE communication processor business to Freescale Semiconductor, including the Comcerto TM 100, 1000 and 2000 product families of multicore embedded processors.
Sign-up for MACOM Announces Definitive Agreement to Sell Mindspeed CPE Communications Processor Business to Freescale Semiconductor investment picks
LOWELL, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- M/A-COM Technology Solutions Holdings, Inc. (Nasdaq:MTSI) (MACOM), a leading supplier of high performance RF, microwave, and millimeter wave products, today announced that its subsidiary Mindspeed Technologies, Inc. has completed the sale of its CPE communication processor business to Freescale Semiconductor, including the Comcerto TM 100, 1000 and 2000 product families of multicore embedded processors.
Sign-up for MACOM Completes Sale of Mindspeed CPE Communications Processor Business to Freescale Semiconductor investment picks
LOWELL, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- M/A-COM Technology Solutions Holdings, Inc. (Nasdaq:MTSI) ("MACOM"), a leading supplier of high performance analog semiconductor solutions, today announced a correction to its fiscal third quarter 2014 guidance for non-GAAP earnings per diluted share as described in its April 29, 2014 earnings press release to be "between $0.30 and $0.33" as announced on MACOM's publicly-webcast earnings teleconference held later that same day.
Sign-up for MACOM Issues Correction to Fiscal Second Quarter Earnings Press Release to Correct Fiscal Third Quarter Guidance for Non-GAAP Earnings Per Diluted Share to be Between $0.30 and $0.33 investment picks
LOWELL, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- M/A-COM Technology Solutions Holdings, Inc. (Nasdaq:MTSI) ("MACOM"), a leading supplier of high performance, RF, microwave, and millimeter wave products, today announced it will release second quarter fiscal 2014 financial results on Tuesday, April 29, 2014 after the market close.
Sign-up for MACOM to Announce Second Quarter Fiscal 2014 Financial Results on April 29, 2014 investment picks
LOWELL, Mass., May 6, 2014 (GLOBE NEWSWIRE) -- M/A-COM Technology Solutions Holdings, Inc. (Nasdaq:MTSI) (MACOM), a leading supplier of high performance RF, microwave, and millimeter wave products, today announced that management will present at the 42 nd Annual J.
Sign-up for MACOM to Present at the J.P. Morgan Global Technology, Media and Telecom Conference on May 19 investment picks
LOWELL, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- M/A-COM Technology Solutions Holdings, Inc. (Nasdaq:MTSI) (MACOM), a leading supplier of high performance RF, microwave, and millimeter wave products, today announced it will host its inaugural Analyst Day in New York City at the Millennium Broadway Hotel on Thursday, May 29 th .
Sign-up for MACOM to Webcast Inaugural Analyst Day on May 29, 2014 investment picks
ROCKVILLE, Md., April 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, May 6, 2014, the Company will release its financial results for the quarter ended March 31, 2014.
Sign-up for MacroGenics Announces Date of First Quarter 2014 Financial Results Conference Call investment picks
ROCKVILLE, Md., April 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART®) protein, has potent activity against colorectal cancer cells both in vitro and in vivo .
Sign-up for MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting investment picks
ROCKVILLE, Md., May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART®) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders.
Sign-up for MacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014 investment picks
Clinical study of first DART, MGD006, to commence in Second Quarter 2014 Phase 3 margetuximab gastroesophageal "MAGENTA" study poised for initiation in second half 2014 ROCKVILLE, Md., May 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate progress update and reported financial results for the quarter ended March 31, 2014.
Sign-up for MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results investment picks
ROCKVILLE, Md., April 1, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13 th Annual Needham Healthcare Conference.
Sign-up for MacroGenics to Present at the 13th Annual Needham Healthcare Conference investment picks
ROCKVILLE, Md., May 7, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO, and Jim Karrels, Vice President and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference.
Sign-up for MacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference investment picks
ROCKVILLE, Md., March 31, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on its colorectal cancer product candidate, MGD007, will be presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
Sign-up for MacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting investment picks
ROCKVILLE, Md., April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) , a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will present pre-clinical data on its novel DART® candidate for the treatment of autoimmune disorders, MGD010, at IMMUNOLOGY 2014, the American Association of Immunologists Annual Meeting, in Pittsburgh, PA.
Sign-up for MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: M.D.C. Holdings Provides Preliminary Update On Net New Home Orders In Advance Of Milken Institute Global Conference to MacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry